Brian K McFarlin, Andrea L Henning, Erin M Bowman, Melody A Gary, Kimberly M Carbajal
{"title":"口服以孢子为基础的益生菌补充与餐后饮食内毒素、甘油三酯和疾病风险生物标志物的发生率降低相关。","authors":"Brian K McFarlin, Andrea L Henning, Erin M Bowman, Melody A Gary, Kimberly M Carbajal","doi":"10.4291/wjgp.v8.i3.117","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To determine if 30-d of oral spore-based probiotic supplementation could reduce dietary endotoxemia.</p><p><strong>Methods: </strong>Apparently healthy men and women (<i>n</i> = 75) were screened for post-prandial dietary endotoxemia. Subjects whose serum endotoxin concentration increased by at least 5-fold from pre-meal levels at 5-h post-prandial were considered \"responders\" and were randomized to receive either placebo (rice flour) or a commercial spore-based probiotic supplement [Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans, and Bacillus licheniformis, and Bacillus clausii] for 30-d. The dietary endotoxemia test was repeated at the conclusion of the supplementation period. Dietary endotoxin (LAL) and triglycerides (enzymatic) were measured using an automated chemistry analyzer. Serum disease risk biomarkers were measured using bead-based multiplex assays (Luminex and Milliplex) as secondary, exploratory measures.</p><p><strong>Results: </strong>Data were statistically analyzed using repeated measures ANOVA and a <i>P</i> < 0.05. We found that spore-based probiotic supplementation was associated with a 42% reduction in endotoxin (12.9 ± 3.5 <i>vs</i> 6.1 ± 2.6, <i>P</i> = 0.011) and 24% reduction in triglyceride (212 ± 28 <i>vs</i> 138 ± 12, <i>P</i> = 0.004) in the post-prandial period Placebo subjects presented with a 36% increase in endotoxin (10.3 ± 3.4 <i>vs</i> 15.4 ± 4.1, <i>P</i> = 0.011) and 5% decrease in triglycerides (191 ± 24 <i>vs</i> 186 ± 28, <i>P</i> = 0.004) over the same post-prandial period. We also found that spore-based probiotic supplementation was associated with significant post-prandial reductions in IL-12p70 (24.3 ± 2.2 <i>vs</i> 21.5 ± 1.7, <i>P</i> = 0.017) and IL-1β (1.9 ± 0.2 <i>vs</i> 1.6 ± 0.1, <i>P</i> = 0.020). Compared to placebo post supplementation, probiotic subject had less ghrelin (6.8 ± 0.4 <i>vs</i> 8.3 ± 1.1, <i>P</i> = 0.017) compared to placebo subjects.</p><p><strong>Conclusion: </strong>The key findings of the present study is that oral spore-based probiotic supplementation reduced symptoms indicative of \"leaky gut syndrome\".</p>","PeriodicalId":23760,"journal":{"name":"World Journal of Gastrointestinal Pathophysiology","volume":"8 3","pages":"117-126"},"PeriodicalIF":0.0000,"publicationDate":"2017-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4291/wjgp.v8.i3.117","citationCount":"35","resultStr":"{\"title\":\"Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers.\",\"authors\":\"Brian K McFarlin, Andrea L Henning, Erin M Bowman, Melody A Gary, Kimberly M Carbajal\",\"doi\":\"10.4291/wjgp.v8.i3.117\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To determine if 30-d of oral spore-based probiotic supplementation could reduce dietary endotoxemia.</p><p><strong>Methods: </strong>Apparently healthy men and women (<i>n</i> = 75) were screened for post-prandial dietary endotoxemia. Subjects whose serum endotoxin concentration increased by at least 5-fold from pre-meal levels at 5-h post-prandial were considered \\\"responders\\\" and were randomized to receive either placebo (rice flour) or a commercial spore-based probiotic supplement [Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans, and Bacillus licheniformis, and Bacillus clausii] for 30-d. The dietary endotoxemia test was repeated at the conclusion of the supplementation period. Dietary endotoxin (LAL) and triglycerides (enzymatic) were measured using an automated chemistry analyzer. Serum disease risk biomarkers were measured using bead-based multiplex assays (Luminex and Milliplex) as secondary, exploratory measures.</p><p><strong>Results: </strong>Data were statistically analyzed using repeated measures ANOVA and a <i>P</i> < 0.05. We found that spore-based probiotic supplementation was associated with a 42% reduction in endotoxin (12.9 ± 3.5 <i>vs</i> 6.1 ± 2.6, <i>P</i> = 0.011) and 24% reduction in triglyceride (212 ± 28 <i>vs</i> 138 ± 12, <i>P</i> = 0.004) in the post-prandial period Placebo subjects presented with a 36% increase in endotoxin (10.3 ± 3.4 <i>vs</i> 15.4 ± 4.1, <i>P</i> = 0.011) and 5% decrease in triglycerides (191 ± 24 <i>vs</i> 186 ± 28, <i>P</i> = 0.004) over the same post-prandial period. We also found that spore-based probiotic supplementation was associated with significant post-prandial reductions in IL-12p70 (24.3 ± 2.2 <i>vs</i> 21.5 ± 1.7, <i>P</i> = 0.017) and IL-1β (1.9 ± 0.2 <i>vs</i> 1.6 ± 0.1, <i>P</i> = 0.020). Compared to placebo post supplementation, probiotic subject had less ghrelin (6.8 ± 0.4 <i>vs</i> 8.3 ± 1.1, <i>P</i> = 0.017) compared to placebo subjects.</p><p><strong>Conclusion: </strong>The key findings of the present study is that oral spore-based probiotic supplementation reduced symptoms indicative of \\\"leaky gut syndrome\\\".</p>\",\"PeriodicalId\":23760,\"journal\":{\"name\":\"World Journal of Gastrointestinal Pathophysiology\",\"volume\":\"8 3\",\"pages\":\"117-126\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4291/wjgp.v8.i3.117\",\"citationCount\":\"35\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Gastrointestinal Pathophysiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4291/wjgp.v8.i3.117\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Pathophysiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4291/wjgp.v8.i3.117","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 35
摘要
目的:确定30天的口服孢子型益生菌补充剂是否可以减少膳食内毒素血症。方法:对表面健康的男性和女性(n = 75)进行餐后膳食内毒素血症筛查。血清内毒素浓度在餐后5小时较餐前水平增加至少5倍的受试者被认为是“应答者”,并被随机分配接受安慰剂(米粉)或商业孢子益生菌补充剂[芽孢杆菌(HU36),枯草芽孢杆菌(HU58),凝固性芽孢杆菌,地衣芽孢杆菌和克劳氏芽孢杆菌]30天。补充期结束时重复饲料内毒素血症试验。采用自动化学分析仪测定食物内毒素(LAL)和甘油三酯(酶)。血清疾病风险生物标志物采用基于头部的多重试验(Luminex和Milliplex)作为次要的探索性措施进行测量。结果:资料采用重复测量方差分析,P < 0.05。我们发现spore-based补充益生菌在内毒素降低42%(12.9±3.5 vs 6.1±2.6,P = 0.011),减少24%的甘油三酸酯(212±28 vs 138±12,P = 0.004)餐后时期安慰剂受试者出现内毒素增加36%(10.3±3.4 vs 15.4±4.1,P = 0.011)和5%减少甘油三酯(191±24 vs 186±28日,P = 0.004)在同一餐后时期。我们还发现,以孢子为基础的益生菌补充与餐后IL-12p70(24.3±2.2 vs 21.5±1.7,P = 0.017)和IL-1β(1.9±0.2 vs 1.6±0.1,P = 0.020)的显著降低相关。与安慰剂组相比,益生菌组的胃饥饿素(ghrelin)较安慰剂组低(6.8±0.4 vs 8.3±1.1,P = 0.017)。结论:本研究的主要发现是口服以孢子为基础的益生菌补充剂可减轻“漏肠综合征”的症状。
Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers.
Aim: To determine if 30-d of oral spore-based probiotic supplementation could reduce dietary endotoxemia.
Methods: Apparently healthy men and women (n = 75) were screened for post-prandial dietary endotoxemia. Subjects whose serum endotoxin concentration increased by at least 5-fold from pre-meal levels at 5-h post-prandial were considered "responders" and were randomized to receive either placebo (rice flour) or a commercial spore-based probiotic supplement [Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans, and Bacillus licheniformis, and Bacillus clausii] for 30-d. The dietary endotoxemia test was repeated at the conclusion of the supplementation period. Dietary endotoxin (LAL) and triglycerides (enzymatic) were measured using an automated chemistry analyzer. Serum disease risk biomarkers were measured using bead-based multiplex assays (Luminex and Milliplex) as secondary, exploratory measures.
Results: Data were statistically analyzed using repeated measures ANOVA and a P < 0.05. We found that spore-based probiotic supplementation was associated with a 42% reduction in endotoxin (12.9 ± 3.5 vs 6.1 ± 2.6, P = 0.011) and 24% reduction in triglyceride (212 ± 28 vs 138 ± 12, P = 0.004) in the post-prandial period Placebo subjects presented with a 36% increase in endotoxin (10.3 ± 3.4 vs 15.4 ± 4.1, P = 0.011) and 5% decrease in triglycerides (191 ± 24 vs 186 ± 28, P = 0.004) over the same post-prandial period. We also found that spore-based probiotic supplementation was associated with significant post-prandial reductions in IL-12p70 (24.3 ± 2.2 vs 21.5 ± 1.7, P = 0.017) and IL-1β (1.9 ± 0.2 vs 1.6 ± 0.1, P = 0.020). Compared to placebo post supplementation, probiotic subject had less ghrelin (6.8 ± 0.4 vs 8.3 ± 1.1, P = 0.017) compared to placebo subjects.
Conclusion: The key findings of the present study is that oral spore-based probiotic supplementation reduced symptoms indicative of "leaky gut syndrome".